Oncogenic kinase signalling.

Cited by (1,008)

Items 401–500 of 1,008

1. Exploring receptor tyrosine kinases-inhibitors in Cancer treatments
   Damilohun Samuel Metibemu, Oluseyi Adeboye Akinloye, Adio Jamiu Akamo, David Ajiboye Ojo, Tolulope Olamide Okeowo, Olaposi Idowu Omotuyi · 2019 · Egyptian Journal of Medical Human Genetics
2. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography–tandem mass spectrometry
   Ray Bakhtiar, Jack J. Lohne, L Ramos, Lakshmi Khemani, Michael Hayes, Francis L. S. Tse · 2002 · Journal of Chromatography B
3. JAK2(V617F): Prevalence in a large Chinese hospital population.
   Xuesong Xu, Qi Zhang, Jian Luo, Shu Xing, Qing-Shan Li, S. Krantz, Xue-Qi Fu, Z. Zhao · 2007 · Blood
4. ROS1 as a ‘druggable’ receptor tyrosine kinase: lessons learned from inhibiting the ALK pathway
   Sai‐Hong Ignatius Ou, Jackie Tan, Yun Yen, Ross Andrew Soo · 2012 · Expert Review of Anticancer Therapy
5. Distinct Cell Cycle Timing Requirements for Extracellular Signal-Regulated Kinase and Phosphoinositide 3-Kinase Signaling Pathways in Somatic Cell Mitosis
   Elisabeth C. Roberts, Paul S. Shapiro, Theresa Stines Nahreini, Gilles Pagès, Jacques Pouysségur, Natalie G. Ahn · 2002 · Molecular and Cellular Biology
6. Activation of Multiple ERBB Family Receptors Mediates Glioblastoma Cancer Stem-like Cell Resistance to EGFR-Targeted Inhibition
   Paul A. Clark, Mari Iida, Daniel M. Treisman, Haviryaji S. G. Kalluri, Sathyapriya Ezhilan, Michael Zorniak, Deric L. Wheeler, John S. Kuo · 2012 · Neoplasia
7. Targeting inflammatory pathways for tumor radiosensitization
   Amit Deorukhkar, Sunil Krishnan · 2010 · Biochemical Pharmacology
8. Post-translational modifications and the Warburg effect
   Taro Hitosugi, J. Chen · 2013 · Oncogene
9. In silico Methods for Design of Kinase Inhibitors as Anticancer Drugs
   Žarko Gagić, Dušan Ružić, Nemanja Djoković, Teodora Djikić, Katarina M. Nikolic · 2020 · Frontiers in Chemistry
10. Evidence for Down-Regulation of Phosphoinositide 3-Kinase/Akt/Mammalian Target of Rapamycin (PI3K/Akt/mTOR)-Dependent Translation Regulatory Signaling Pathways in Ames Dwarf Mice
    Sharp, Z. D., Bartke, A. · 2005 · The Journals of Gerontology Series A: Biological Sciences and Medical Sciences
11. Kinases and Pseudokinases: Lessons from RAF
    Andréy S. Shaw, Alexandr P. Kornev, Jiancheng Hu, Lalima Gagan Ahuja, Susan Serota Taylor · 2014 · Molecular and Cellular Biology
12. Differential Expression of Novel Tyrosine Kinase Substrates during Breast Cancer Development
    Yunhao Chen, Lee‐Yee Choong, Qingsong Lin, Robin Philps, Chee‐Hong Wong, Boon Keong Ang, Yee-Ling Tan, Marie Chiew Shia Loh, Choy-Leong Hew, Nilesh Shah et al. · 2007 · Molecular & Cellular Proteomics
13. Acute and chronic toxicity of six anticancer drugs on rotifers and crustaceans
    Alfredo Parrella, Margherita Lavorgna, Emma Criscuolo, Chiara Russo, Vittorio Fiumano, Marina Isidori · 2014 · Chemosphere
14. Targeting RTK-PI3K-mTOR Axis in Gliomas: An Update
    Mayra Colardo, Marco Segatto, Sabrina Di Bartolomeo · 2021 · International Journal of Molecular Sciences
15. 25 Years of Small Molecular Weight Kinase Inhibitors: Potentials and Limitations
    Doriano Fabbro · 2014 · Molecular Pharmacology
16. Sequential Phosphoproteomic Enrichment through Complementary Metal-Directed Immobilized Metal Ion Affinity Chromatography
    Chia‐Feng Tsai, Chuan‐Chih Hsu, Jo-Nan Hung, Yi-Ting Wang, Wai-Kok Choong, Ming-Yao Zeng, Pei-Yi Lin, Ruo-Wei Hong, Ting‐Yi Sung, Yu‐Ju Chen · 2013 · Analytical Chemistry
17. Ror1 Is a Pseudokinase That Is Crucial for Met-Driven Tumorigenesis
    Alessandra Gentile, Luca Lazzari, Silvia Benvenuti, Livio Trusolino, Paolo Maria Comoglio · 2011 · Cancer Research
18. The molecular physiology of nuclear retinoic acid receptors. From health to disease
    Vanessa Duong, Cécile Rochette‐Egly · 2010 · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease
19. Molecular Basis for Redox Activation of Epidermal Growth Factor Receptor Kinase
    Thu Ha Truong, Peter M.U. Ung, Prakash B. Palde, Candice E. Paulsen, Avner Schlessinger, Kate S. Carroll · 2016 · Cell chemical biology
20. Development of anaplastic lymphoma kinase (ALK) small‐molecule inhibitors for cancer therapy
    Rongshi Li, Stephan Wade Morris · 2007 · Medicinal Research Reviews
21. Molecular characterizations of glioblastoma, targeted therapy, and clinical results to date
    Jayson Bastien, Katharine Anne McNeill, Howard Alan Fine · 2014 · Cancer
22. Involvement of the small protein tyrosine phosphatases TC-PTP and PTP1B in signal transduction and diseases: From diabetes, obesity to cell cycle, and cancer
    Nadia Dubé, Michel L. Tremblay · 2005 · Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics
23. Altered localization and activity of the intracellular tyrosine kinase BRK/Sik in prostate tumor cells
    Jason J. Derry, Gail S. Prins, Vera Ray, Angela L. Tyner · 2003 · Oncogene
24. Formation of E-Cadherin-Mediated Cell-Cell Adhesion Activates Akt and Mitogen Activated Protein Kinase via Phosphatidylinositol 3 Kinase and Ligand-Independent Activation of Epidermal Growth Factor Receptor in Ovarian Cancer Cells
    Pradeep Reddy, Lian Liu, Chong Ren, Peter Lindgren, Karin Boman, Yan Shen, Eva Lundin, Ulrika Ottander, Miia M. Rytinki, Kui Liu · 2005 · Molecular Endocrinology
25. BCR/ABL regulates response to DNA damage: the role in resistance to genotoxic treatment and in genomic instability
    Tomasz Skórski · 2002 · Oncogene
26. Novel Targets for Lung Cancer Therapy: Part I
    Grace Kho Dy, Alex A. Adjei · 2002 · Journal of Clinical Oncology
27. Oncogenic tyrosine kinases and the dna-damage response
    Tomasz Skórski · 2002 · Nature reviews. Cancer
28. The role of protein tyrosine phosphatase 1B in Ras signaling
    Nadia Dubé, Alan Cheng, Michel L. Tremblay · 2004 · Proceedings of the National Academy of Sciences
29. Prognostic Significance of Co-expression of RON and MET Receptors in Node-Negative Breast Cancer Patients
    Wen‐Ying Lee, Helen H.W. Chen, Nan-Haw Chow, Wu‐Chou Su, Pin-Wen Lin, How‐Ran Guo · 2005 · Clinical Cancer Research
30. Hyperactive EGF receptor, Jaks and Stat3 signaling promote enhanced colony-forming ability, motility and migration of cisplatin-resistant ovarian cancer cells
    P Yue, Xiaolei Zhang, David Paladino, B Sengupta, Sarfraz Ahmad, Robert W. Holloway, Susan Blaydes Ingersoll, James Turkson · 2011 · Oncogene
31. Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
    Dunn, E F, Iida, M, Myers, R A, Campbell, D A, Hintz, K A, Armstrong, E A, Li, C, Wheeler, D L · 2011 · Oncogene
32. Solid Tumor Proteome and Phosphoproteome Analysis by High Resolution Mass Spectrometry
    Sara R. Zanivan, Florian Gnad, Sara A. Wickström, Tamar Geiger, Boris Maček, Jürgen Cox, Reinhard Fässler, Matthias Mann · 2008 · Journal of Proteome Research
33. Overexpression and functional alterations of the EphA2 tyrosine kinase in cancer
    Michael S. Kinch, Kelly Carles‐Kinch · 2003 · Clinical & Experimental Metastasis
34. Pin1 Interacts With a Specific Serine-Proline Motif of Hepatitis B Virus X-Protein to Enhance Hepatocarcinogenesis
    Roberta W. C. Pang, Terence K. Lee, Ronnie T. P. Poon, Sheung Tat Fan, Kam‐Bo Wong, Yok‐Lam Kwong, Eric Tse · 2006 · Gastroenterology
35. Inhibition of the Insulin-like Growth Factor-1 Receptor (IGF1R) Tyrosine Kinase as a Novel Cancer Therapy Approach
    Rongshi Li, Alan Pourpak, Stephan Wade Morris · 2009 · Journal of Medicinal Chemistry
36. Itch E3 ubiquitin ligase regulates large tumor suppressor 1 stability
    King Ching Ho, Zhonghua Zhou, Yi‐Min She, Alex Chun, Terry Donald Cyr, Xiaolong Yang · 2011 · Proceedings of the National Academy of Sciences
37. Emerging roles for Rab family GTPases in human cancer
    Wan-Jie Chia, Bor Luen Tang · 2009 · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer
38. The tuberous sclerosis proteins regulate formation of the primary cilium via a rapamycin-insensitive and polycystin 1-independent pathway
    Tiffiney R. Hartman, Dongyan Liu, Jack T. Zilfou, Victoria A. Robb, Tasha A. Morrison, Terry J. Watnick, Elizabeth P. Henske · 2008 · Human Molecular Genetics
39. Clear Cell Sarcoma of the Kidney: Up-regulation of Neural Markers with Activation of the Sonic Hedgehog and Akt Pathways
    Colleen Cutcliffe, Donna S. Kersey, Chiang‐Ching Huang, Yong Zeng, David Otto Walterhouse, Elizabeth Jones Perlman · 2005 · Clinical Cancer Research
40. Applying computational modeling to drug discovery and development
    Kumar, Neil, Hendriks, Bart S., Janes, Kevin A., de Graaf, David, Lauffenburger, Douglas A. · 2006 · Drug Discovery Today
41. Small molecule tools for functional interrogation of protein tyrosine phosphatases
    Rongjun He, Li‐Fan Zeng, Yantao He, Sheng Zhang, Zhong‐Yin Zhang · 2012 · FEBS Journal
42. Targeting PTPs with small molecule inhibitors in cancer treatment
    Zhong‐Xing Jiang, Zhong‐Yin Zhang · 2008 · Cancer and Metastasis Reviews
43. Apatinib-induced protective autophagy and apoptosis through the AKT–mTOR pathway in anaplastic thyroid cancer
    Haoran Feng, Xi Cheng, Jie Kuang, Lingxie Chen, Stanley Yuen, Minmin Shi, Juyong Liang, Baiyong Shen, Zhijian Jin, Jiqi Yan et al. · 2018 · Cell Death and Disease
44. An Electrostatic Engine Model for Autoinhibition and Activation of the Epidermal Growth Factor Receptor (EGFR/ErbB) Family
    Stuart McLaughlin, Steven O. Smith, Michael J. Hayman, Diana Murray · 2005 · The Journal of General Physiology
45. Pro-metastatic signaling by c-Met through RAC-1 and reactive oxygen species (ROS)
    Daniela Aleida Ferraro, Simona Corso, E Fasano, Emiliano Panieri, Rosaria Santangelo, Silvia Borrello, Silvia Giordano, Giovambattista Pani, Tommaso Galeotti · 2006 · Oncogene
46. Expression, mutation and copy number analysis of platelet-derived growth factor receptor A (PDGFRA) and its ligand PDGFA in gliomas
    Olga Martinho, Adhemar Longatto‐Filho, M. B. Lambros, Albino M Martins, Celine Marques Pinheiro, Andyara Sepulveda Lobato da Silva, Fernando Pardal, Julia A de Amorim, Alan G. Mackay, Fernanda Milanezi et al. · 2009 · British Journal of Cancer
47. Turning germ cells into stem cells.
    P. Donovan, M. de Miguel · 2003 · Current Opinion in Genetics and Development
48. MET: A Critical Player in Tumorigenesis and Therapeutic Target
    Graveel, C. R., Tolbert, D., Vande Woude, G. F. · 2013 · Cold Spring Harbor Perspectives in Biology
49. Enhanced epidermal growth factor receptor activation in human cholangiocarcinoma cells
    Jung‐Hwan Yoon, Geum‐Youn Gwak, Hyo-Suk Lee, Steven F. Bronk, Nathan W. Werneburg, Gregory James Gores · 2004 · Journal of Hepatology
50. PI3K/Akt signaling pathway is essential for de novo hair follicle regeneration
    Chen, Yu, Fan, Zhimeng, Wang, Xiaoxiao, Mo, Miaohua, Zeng, Shu Bin, Xu, Ren-He, Wang, Xusheng, Wu, Yaojiong · 2020 · Stem Cell Research & Therapy
51. The phosphorylation status and anti‐apoptotic activity of Bcl‐2 are regulated by ERK and protein phosphatase 2A on the mitochondria
    Yuki Tamura, Siro Simizu, Hiroyuki Osada · 2004 · FEBS Letters
52. Autocrine- and paracrine-activated receptor tyrosine kinases in classic Hodgkin lymphoma
    Christoph Renné, Klaus Willenbrock, Ralf Küppers, Martin‐Leo Hansmann, Andreas Bräuninger · 2005 · Blood
53. Clinical Proteomics: From Biomarker Discovery and Cell Signaling Profiles to Individualized Personal Therapy
    K. Calvo, L. Liotta, E. Petricoin · 2005 · Bioscience Reports
54. Dual Inhibition of Focal Adhesion Kinase and Epidermal Growth Factor Receptor Pathways Cooperatively Induces Death Receptor-mediated Apoptosis in Human Breast Cancer Cells
    Vita Golubovskaya, Lucia Beviglia, Li‐Hui Xu, Henry Shelton Earp, Rolf J. Craven, William G. Cance · 2002 · Journal of Biological Chemistry
55. Small molecule tyrosine kinase inhibitors: clinical development of anticancer agents
    Alexander Laird, Julie M. Cherrington · 2003 · Expert Opinion on Investigational Drugs
56. Targeting Cancer with Small-Molecular-Weight Kinase Inhibitors
    Doriano Fabbro, Sandra W. Cowan‐Jacob, Henrik Möbitz, Georg Martiny‐Baron · 2011 · Methods in molecular biology
57. Personalized Cancer Therapy With Selective Kinase Inhibitors: An Emerging Paradigm in Medical Oncology
    Ultan McDermott, Jeff Settleman · 2009 · Journal of Clinical Oncology
58. Comprehensive and Reproducible Phosphopeptide Enrichment Using Iron Immobilized Metal Ion Affinity Chromatography (Fe-IMAC) Columns
    Benjamin Ruprecht, Heiner Koch, Guillaume Médard, Max Mundt, Bernhard Küster, Simone Lemeer · 2014 · Molecular & Cellular Proteomics
59. Unraveling the Anticancer Effect of Curcumin and Resveratrol
    Aline Renata Pavan, Gabriel Silva, Daniela Hartmann Jornada, Diego Eidy Chiba, Guilherme Fernandes, Chung Man Chin, Jean Leandro dos Santos · 2016 · Nutrients
60. Choline Kinase Activation Is a Critical Requirement for the Proliferation of Primary Human Mammary Epithelial Cells and Breast Tumor Progression
    Ana Ramı́rez de Molina, Mónica Báñez-Coronel, Ruth Gutiérrez, Agustı́n Rodrı́guez-González, David Olmeda, Diego Megı́as, Juan Carlos Lacal · 2004 · Cancer Research
61. Clinical translation of nuclear export inhibitors in cancer
    William T. Senapedis, Erkan Baloglu, Yosef Landesman · 2014 · Seminars in Cancer Biology
62. Monitoring cancer treatment with PET/CT: does it make a difference?
    Wolfgang Weber, Robert A. Figlin · 2007 · PubMed
63. Gastric GI stromal tumors (GISTs): The role of surgery in the era of targeted therapy
    Michael Charles Heinrich, Christopher L. Corless · 2005 · Journal of Surgical Oncology
64. Selectivity of Docking Sites in MAPK Kinases
    Bardwell, A. Jane, Frankson, Erlynn, Bardwell, Lee · 2009 · Journal of Biological Chemistry
65. Possible dominant-negative mutation of the SHIP gene in acute myeloid leukemia
    Luo, J-M, Yoshida, H, Komura, S, Ohishi, N, Pan, L, Shigeno, K, Hanamura, I, Miura, K, Iida, S, Ueda, R et al. · 2003 · Leukemia
66. Design, synthesis and biological evaluation of thiazolidinone derivatives as potential EGFR and HER-2 kinase inhibitors
    Peng‐Cheng Lv, Changfang Zhou, Jin Chen, Penggang Liu, Kairui Wang, Wenjun Mao, Huan‐Qiu Li, Ying Yang, Jing Xiong, Hai‐Liang Zhu · 2009 · Bioorganic & Medicinal Chemistry
67. Entrectinib: an orally available, selective tyrosine kinase inhibitor for the treatment of NTRK, ROS1, and ALK fusion-positive solid tumors
    Dazhi Liu, Michael David Offin, Stephen J. Harnicar, Bob T. Li, Alexander Edward Dela Cruz Drilon · 2018 · Therapeutics and Clinical Risk Management
68. Cool-1 functions as an essential regulatory node for EGFreceptor- and Src-mediated cell growth
    Qiyu Feng, Dan Baird, Xu Peng, Jianbin Wang, Thi K. Ly, Jun‐Lin Guan, Richard A. Cerione · 2006 · Nature Cell Biology
69. Sensitive kinase assay linked with phosphoproteomics for identifying direct kinase substrates
    Liang Xue, Wen‐Horng Wang, Anton B. Iliuk, Lianghai Hu, Jacob Anthony Galan, Shuai Yu, Michael Hans, Robert L. Geahlen, W. Andy Tao · 2012 · Proceedings of the National Academy of Sciences
70. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach
    Robert J. Coffey, Mary Kay Washington, Christopher L. Corless, Michael Charles Heinrich · 2007 · Journal of Clinical Investigation
71. Tetrabromocinnamic Acid (TBCA) and Related Compounds Represent a New Class of Specific Protein Kinase CK2 Inhibitors
    Mario Angelo Pagano, Giorgia Poletto, Giovanni Di Maira, Giorgio Cozza, Maria Ruzzene, Stefania Sarno, Jenny Bain, Matthew Elliott, Stefano Moro, Giuseppe Zagotto et al. · 2006 · ChemBioChem
72. Phosphotyrosyl Mimetics in the Development of Signal Transduction Inhibitors
    Terrence R. Burke, Kyeong Lee · 2003 · Accounts of Chemical Research
73. PTP1B and TC-PTP: regulators of transformation and tumorigenesis
    Matthew Stuible, Karen M. Doody, Michel L. Tremblay · 2008 · Cancer and Metastasis Reviews
74. Therapeutic progression of quinazolines as targeted chemotherapeutic agents
    Ranju Bansal, Anjleena Malhotra · 2020 · European Journal of Medicinal Chemistry
75. A structure-based model for ligand binding and dimerization of EGF receptors
    Peter Klein, Dawn Mattoon, Mark A. Lemmon, Joseph Schlessinger · 2004 · Proceedings of the National Academy of Sciences
76. Activation of the PKB/AKT Pathway by ICAM-2
    Omar D. Perez, Shigemi M. Kinoshita, Yasumichi Hitoshi, Donald G. Payan, Toshio Kitamura, Garry P. Nolan, James B. Lorens · 2002 · Immunity
77. Human members of the eukaryotic protein kinase family
    Mitchell S. Kostich, Jessie M. English, Vincent Madison, Ferdous Gheyas, Luquan Wang, Ping Qiu, Jonathan R. Greene, Thomas M. Laz · 2002 · Genome biology
78. Post-translational modifications of naturally processed MHC-binding epitopes
    Víctor H. Engelhard, Michelle L. Altrich-VanLith, Marina Ostankovitch, Angela L. Zarling · 2005 · Current Opinion in Immunology
79. Small‐Molecule Inhibitors of PDK1
    Christian Peifer, Dario R. Alessi · 2008 · ChemMedChem
80. Sialylation of EGFR by the ST6Gal-I sialyltransferase promotes EGFR activation and resistance to gefitinib-mediated cell death
    Colleen M. Britain, Andrew T. Holdbrooks, Joshua Charles Anderson, Christopher Douglas Willey, Susan L. Bellis · 2018 · Journal of Ovarian Research
81. Functional miRNAs in breast cancer drug resistance
    Weizi Hu, Chunli Tan, Yunjie He, Guangqin Zhang, Yong Xu, Jinhai Tang · 2018 · OncoTargets and Therapy
82. Activation of the p70 S6 Kinase and Phosphorylation of the 4E-BP1 Repressor of mRNA Translation by Type I Interferons
    Fatima Lekmine, Shahab Uddin M.S., Antonella Sassano, Simrit Parmar, Saskia M. Brachmann, Beata Majchrzak, Nahum Sonenberg, Nissim Hay, Eleanor N. Fish, Leonidas C. Platanias · 2003 · Journal of Biological Chemistry
83. Pleuro-pulmonary Solitary Fibrous Tumors
    Laura Schirosi, Sylvie Lantuéjoul, Alberto Cavazza, Bruno Murer, Pierre Yves Brichon, Mario Migaldi, Giuliana Sartori, Alessandro Sgambato, Giulio Rossi · 2008 · The American Journal of Surgical Pathology
84. Erlotinib Effectively Inhibits JAK2V617F Activity and Polycythemia Vera Cell Growth
    Zhe Li, Mingjiang Xu, Shu Xing, Wan‐Ting Ho, Takefumi Ishii, Qingshan Li, Xueqi Fu, Zhizhuang Joe Zhao · 2006 · Journal of Biological Chemistry
85. Suppression of fatty acid synthase in MCF-7 breast cancer cells by tea and tea polyphenols: a possible mechanism for their hypolipidemic effects
    C-W Yeh, W-J Chen, C-T Chiang, S-Y Lin-Shiau, J-K Lin · 2003 · The Pharmacogenomics Journal
86. Prolyl isomerase Pin1 as a molecular target for cancer diagnostics and therapeutics
    Kun Ping Lu · 2003 · Cancer Cell
87. Discovery of thieno[2,3-d]pyrimidine-based derivatives as potent VEGFR-2 kinase inhibitors and anti-cancer agents
    Souad A. El‐Metwally, Mohsen M. Abou-El-Regal, Ibrahim H. Eissa, Ahmed B. M. Mehany, Hazem A. Mahdy, Hazem Elkady, Alaa Elwan, Eslam B. Elkaeed · 2021 · Bioorganic Chemistry
88. The emerging role of the PI3-K-Akt pathway in prostate cancer progression
    L. Li, Michael Ittmann, Gustavo Ayala, Ming‐Jer Tsai, R. J. Amato, Thomas M. Wheeler, Brian J. Miles, Dov Kadmon, Timothy C. Thompson · 2005 · Prostate Cancer and Prostatic Diseases
89. Mutations of genes in the receptor tyrosine kinase (RTK)/RAS-BRAF signal transduction pathway in therapy-related myelodysplasia and acute myeloid leukemia
    Debes Hammershaimb Christiansen, Mette Klarskov Andersen, Fraol Zeleke Desta, J Pedersen-Bjergaard · 2005 · Leukemia
90. The Loss of PTEN Allows TCR αβ Lineage Thymocytes to Bypass IL-7 and Pre-TCR–mediated Signaling
    Thijs J. Hagenbeek, Marianne Naspetti, Fabrice Malergue, Fabien Garçon, Jacques A. Nunès, Kitty B.J.M. Cleutjens, Jan Trapman, Paul Krimpenfort, Hergen Spits · 2004 · The Journal of Experimental Medicine
91. Discoidin Domain Receptor 1 Controls Growth and Adhesion of Mesangial Cells
    Cyrile Anne Curat, Wolfgang F. Vogel · 2002 · Journal of the American Society of Nephrology
92. Preferential Inhibition of Akt and Killing of Akt-Dependent Cancer Cells by Rationally Designed Phosphatidylinositol Ether Lipid Analogues
    S. Sianna Castillo, John Brognard, Pavel A. Petukhov, Chunyu Zhang, Junji Tsurutani, Courtney A. Granville, Min Li, Michael Jung, Kip A. West, Joell G. Gills et al. · 2004 · Cancer Research
93. Autoinhibition Control
    Joseph Schlessinger · 2003 · Science
94. Mediation of the DCC Apoptotic Signal by DIP13α
    Liu, Jiayou, Yao, Fayi, Wu, Ruping, Morgan, Michael, Thorburn, Andrew, Finley, Russell L., Chen, Yong Q. · 2002 · Journal of Biological Chemistry
95. Colon cancer metastasis: MACC1 and Met as metastatic pacemakers
    Franziska Arlt, Ulrike Stein · 2009 · The International Journal of Biochemistry & Cell Biology
96. The novel receptor tyrosine kinase Axl is constitutively active in B-cell chronic lymphocytic leukemia and acts as a docking site of nonreceptor kinases: implications for therapy
    Asish K. Ghosh, Charla R. Secreto, Justin C. Boysen, Traci Sassoon, Tait D. Shanafelt, Debabrata Mukhopadhyay, Neil E. Kay · 2010 · Blood
97. CBL Exon 8/9 Mutants Activate the FLT3 Pathway and Cluster in Core Binding Factor/11q Deletion Acute Myeloid Leukemia/Myelodysplastic Syndrome Subtypes
    Carola Reindl, Hilmar Quentmeier, Konstantin Petropoulos, Philipp A. Greif, Tobias Benthaus, Bob Argiropoulos, Gudrun Mellert, Sridhar Vempati, Justus Duyster, Christian Buske et al. · 2009 · Clinical Cancer Research
98. Mammalian target of rapamycin inhibition as a therapeutic strategy in the management of urologic malignancies
    Jorge Alberto Garcia, David Danielpour · 2008 · Molecular Cancer Therapeutics
99. Kinases, Homology Models, and High Throughput Docking
    David Diller, Rixin Li · 2003 · Journal of Medicinal Chemistry
100. PI 3-kinase, mTOR, protein synthesis and cancer
     Peter K. Vogt · 2001 · Trends in Molecular Medicine